Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart failure with preserved systolic function.
Epistemonikos ID: 31ee0dfa4e7e5d7c4f34ec7cdbd39b98c911a0e0
First added on: Dec 20, 2022